Biotech – the red-hot, high risk investment story

Biotech - the red-hot, high risk investment story

Biotech stocks have been booming over the last few years. Anyone who has invested will have made some very respectable profits. And it's a bull market that's set to continue for some time yet.

How to invest in the next big medical breakthrough

There is currently no cure for MS, Alzheimer’s and Parkinson’s diseases but research gallops on. There will be big rewards for the first drug company to break through, says Dr Mike Tubbs.

The fountain of youth will spout money for investors

Life expectancy has doubled in just a few generations, and the trend will continue,  Jim Mellon tells Merryn Somerset Webb. That’s an opportunity for investors.

How to invest in the fight against cancer

A new generation of anti-cancer drugs looks promising. There are four main ways to invest, with varying levels of risk. Dr Michael Tubbs explains.

Buy into this exceptional healthcare trust

Investors have an opportunity to buy into an exceptional trust in an undervalued growth sector. They should take it, says Max King.

How to profit as Britain piles on the pounds

The world is getting fatter – and with no easy solution to obesity in sight, investing in healthcare providers and food and drink makers could bring big gains, says Jonathan Compton.

Invest in cutting-edge healthcare

Max King looks at one fund allowing investors to put their money in cutting-edge medical research.

The pharma price-gouging scandal

Pharmaceutical companies have hit the headlines for hiking prices for life-saving drugs by shocking amounts. What’s going on? Simon Wilson reports.

Three promising sectors for 2017

Max King tips a host of funds in various sectors to do well in the forthcoming year.

Lilly fails Alzheimer’s test

Eli Lilly’s new treatment has proved ineffective in late-stage trials – yet another blow for a struggling sector, says Ben Judge.

Who will prosper under Trump?

Now that the markets have got over the shock of a Trump victory in the US presidential election, David C Stevenson looks at which funds to buy.

Showing page 1 of 9